Noom for Women: Prescribing Data, Outcome Signals, and What the Complaints Actually Say

Is Noom Legit? An Honest Answer Before You Spend a Dollar

Noom is a real company, incorporated in New York, with real licensed clinicians operating through its Noom Med division. It is not a scam in the sense of being a fraudulent shell. The coaching app has been operating since 2008 and has genuine peer-reviewed research behind the behavioral-psychology model it uses for caloric tracking.

The harder question is whether Noom delivers on its specific promises to women seeking GLP-1 medications in 2025, and that answer is more complicated.

What Noom Med Actually Is

Noom Med launched in 2023 as the company's telehealth prescribing arm. Through Noom Med, a user can be evaluated by a licensed clinician and, if eligible, prescribed a GLP-1 receptor agonist such as semaglutide. The prescribing workflow is asynchronous in many cases, meaning a clinician reviews a form rather than conducting a live video visit. Some users receive a synchronous consult, but this is not guaranteed.

The GLP-1 medications dispensed through Noom Med have at times included compounded semaglutide from 503B outsourcing facilities, a category the FDA has flagged as carrying quality and safety risks distinct from brand-name products. As of early 2025, the FDA declared the semaglutide shortage resolved, which has significant implications for whether compounded versions remain legally permissible.

What the Coaching App Research Actually Shows

The behavioral model Noom uses draws on cognitive behavioral therapy principles. A 2016 study in Scientific Reports by Michaelides et al. followed 35,921 Noom users and found that 78% lost weight over an 18-week period, with greater coach interaction correlating with larger losses. This is observational data from Noom's own dataset, not an independent randomized controlled trial.

No peer-reviewed RCT of Noom Med's combined coaching-plus-GLP-1 model in women has been published as of July 2025. That is an evidence gap you deserve to know about before enrolling.

What the Complaint Data Actually Shows

BBB complaint volume is not a clinical outcome measure, but it is a signal worth reading carefully.

As of mid-2025, Noom holds a 1.13 out of 5 star customer rating on the Better Business Bureau with more than 2,300 complaints filed. The BBB has given Noom an "A" accreditation rating, which reflects complaint response practices rather than customer satisfaction.

The Most Common Complaint Categories

Reading through the complaint narratives reveals patterns that matter specifically to women making health and financial decisions:

Billing and auto-renewal. The largest complaint category involves charges continuing after cancellation attempts. Multiple complainants describe difficulty reaching customer service to stop recurring charges. For women on a fixed prescribing budget, this creates a real financial risk.

Prescription delays and fulfillment gaps. A second common theme involves delays between a prescribing visit and medication shipment, sometimes stretching to several weeks. For a woman managing PCOS-related insulin resistance or perimenopause-related weight gain, a multi-week gap in GLP-1 dosing is clinically meaningful because consistency of dosing affects tolerability and efficacy.

Coaching quality inconsistency. Several complaints describe coaches being unavailable, slow to respond, or replaced without notice. This matters because the behavioral coaching component is theoretically the differentiated value Noom offers over a plain telehealth GLP-1 prescription.

What Noom Has Said in Response

Noom's standard BBB response typically acknowledges the complaint and offers a refund or service credit. The company has not published a public-facing analysis of complaint trends or systemic remediation steps as of July 2025.

A useful framework for evaluating any telehealth weight-loss platform: separate the prescribing quality (is there a real clinician, a real consult, and a real follow-up protocol?) from the product quality (does the medication arrive on time, is it what was prescribed, and is the dose monitored appropriately?). Noom complaints cluster in the product-quality category more than the prescribing-quality category, which suggests the clinical arm functions better than the logistics arm.

Sex-Specific Physiology: Why GLP-1 Prescribing Is Not the Same for Every Woman

GLP-1 receptor agonists were studied primarily in mixed-sex populations in the major cardiovascular outcomes trials. The STEP 1 trial of semaglutide 2.4 mg enrolled 1,961 participants, of whom approximately 74% were women. Women in STEP 1 lost a mean of 14.9% body weight versus 16.4% in men over 68 weeks, a modest sex difference, but the trial was not powered to detect differential efficacy by sex.

Menstrual Cycle Effects

GLP-1 agonists reduce gastric emptying and caloric intake. During the luteal phase of the menstrual cycle, progesterone already slows gastric motility. Women starting semaglutide in the luteal phase may experience more pronounced nausea and gastrointestinal side effects than those starting in the follicular phase. No Noom Med protocol documentation publicly addresses this. A prescribing platform serving women should.

PCOS: A High-Stakes Use Case

PCOS affects roughly 1 in 10 women of reproductive age and is characterized by insulin resistance, hyperandrogenism, and anovulation. GLP-1 agonists improve insulin sensitivity and reduce androgen levels in women with PCOS, making them a biologically rational treatment. A 2023 meta-analysis in Fertility and Sterility found that GLP-1 agonists reduced BMI and fasting insulin in women with PCOS and may improve menstrual regularity.

Noom Med does not appear to have a PCOS-specific intake protocol or a documented pathway for coordinating GLP-1 prescribing with a woman's gynecologist or reproductive endocrinologist. For a woman with PCOS who is also managing fertility goals, this is a real gap.

Perimenopause and Menopause

During perimenopause, declining estrogen shifts fat distribution toward the abdomen and impairs insulin sensitivity. The Menopause Society's 2023 position statement on menopause and obesity notes that weight gain during the menopausal transition is common and that metabolic risk rises independently of total body weight. GLP-1 agonists are not contraindicated in postmenopausal women and may offer cardiovascular benefit in this group, as suggested by the SELECT trial data.

Noom Med does not publicly document a menopause-specific prescribing or coaching protocol. A postmenopausal woman prescribed semaglutide through Noom Med receives the same behavioral coaching curriculum as a 28-year-old, which may not address the specific dietary, hormonal, and musculoskeletal context of her life stage.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know Before Starting a GLP-1 Through Any Telehealth Platform

GLP-1 receptor agonists are contraindicated in pregnancy. This is not a precautionary footnote. Animal studies of semaglutide and liraglutide show fetal harm at doses below the human therapeutic range, including reduced fetal growth, skeletal abnormalities, and increased fetal mortality. Human data in pregnancy is limited but does not suggest safety.

Pregnancy Category and Human Data

Semaglutide (Ozempic, Wegovy) carries an FDA label stating it should be discontinued at least 2 months before a planned pregnancy. Tirzepatide (Zepbound) labeling recommends discontinuation at least 1 month before conception. These washout windows exist because GLP-1 agonists have long half-lives and may affect placental function.

ACOG has not issued a formal practice bulletin endorsing GLP-1 use in pregnancy. The FDA's label for semaglutide injection states: "Based on animal data, OZEMPIC may cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus."

Lactation Transfer

Semaglutide is a large peptide molecule. Transfer into human breast milk is expected to be low based on molecular weight, but no adequately powered human lactation study exists. The FDA label advises against use during breastfeeding because of the absence of safety data and the potential for adverse effects in a nursing infant. If you are breastfeeding, this is a medication you should not take through any telehealth platform, Noom or otherwise, without direct consultation with your prescribing physician and your infant's pediatrician.

Contraception Requirements

Women of reproductive potential who are prescribed semaglutide or tirzepatide through Noom Med should use reliable contraception throughout treatment. GLP-1 agonists may reduce the absorption of oral contraceptives by altering gastric emptying. A pharmacokinetic sub-study found that semaglutide reduced the Cmax of ethinyl estradiol and levonorgestrel in a combined oral contraceptive, though overall exposure (AUC) was within acceptable limits. Using a non-oral contraceptive method such as an IUD or implant removes this variable entirely.

Noom Med's intake forms ask whether you are pregnant or trying to conceive. What is less clear from publicly available documentation is whether the platform has a structured protocol for women who become pregnant during treatment or who are actively trying to conceive while on a GLP-1.

Who Noom May Work For and Who Should Look Elsewhere

This is a life-stage-specific assessment, not a blanket endorsement or dismissal.

Women Who May Find Noom Useful

Women with a BMI >27 with at least one weight-related comorbidity, or BMI >30, who want a combined behavioral coaching and GLP-1 approach may find the Noom Med model convenient if the logistics arm works for them. The FDA's approval threshold for GLP-1 use in chronic weight management is BMI >27 with a comorbidity such as type 2 diabetes, hypertension, or dyslipidemia.

Women who have already tried lifestyle modification alone and want to add pharmacotherapy, and who are comfortable with asynchronous telehealth, may find the model adequate.

Women Who Should Proceed With Caution or Seek an Alternative

Women with PCOS who are trying to conceive. GLP-1 agonists can improve ovulation in women with PCOS, which means fertility may return faster than expected. A woman not using reliable contraception who starts semaglutide through Noom Med without coordinated reproductive care is at real risk of an unintended pregnancy during treatment with a teratogenic medication.

Perimenopausal and postmenopausal women. The behavioral curriculum does not appear calibrated for hormonal context. A platform that also addresses hormone therapy, sleep, and bone density in the menopausal transition would be more appropriate for this group.

Women with a history of eating disorders. GLP-1 agonists suppress appetite through central and peripheral mechanisms. This can be therapeutically useful but may also interact unpredictably with restrictive or disordered eating patterns. The STEP trial programs excluded participants with active eating disorders, as noted in the STEP 1 inclusion/exclusion criteria. Noom's intake does not appear to screen systematically for eating disorder history in its publicly documented workflow.

Women planning pregnancy within 6 months. The contraindication and washout period make this a non-starter through any telehealth GLP-1 platform without close specialist coordination.

The Compounding Question: What Women Prescribed Through Noom Med Should Know

During the FDA-declared semaglutide shortage, Noom Med dispensed compounded semaglutide from 503B facilities. The FDA's guidance on compounded GLP-1 drugs makes clear that compounded semaglutide is not FDA-approved, has not undergone the same manufacturing quality review as Wegovy or Ozempic, and may differ in dose accuracy, purity, and sterility.

With the shortage resolved, the legal basis for prescribing compounded semaglutide has narrowed substantially. Women should ask Noom Med directly whether they are receiving a compounded or brand-name product, what 503B facility it comes from, and whether that facility has any FDA warning letters on record. The FDA's database of 503B inspections and warning letters is publicly searchable.

What Noom Does Not Tell You: Evidence Gaps and Missing Data

Transparency is a clinical trust signal. Here is what is missing from the public record:

No published peer-reviewed outcome data from Noom Med. The 2016 Michaelides observational study covers the coaching app, not the GLP-1 prescribing arm. Noom Med has not published weight-loss outcomes, dropout rates, adverse event rates, or medication adherence data in a peer-reviewed journal. For a platform that has been operating since 2023, this absence is notable.

No sex-stratified outcome reporting. Even if Noom Med were to publish outcomes, without sex-stratified data you cannot know whether the combined coaching-plus-GLP-1 model works differently in women than in men. Women have been historically underrepresented in weight-loss pharmacotherapy trials, a gap documented in a 2021 analysis in Obesity Reviews, and telehealth platform reporting has not filled it.

No PCOS-specific or menopause-specific outcome data. The populations where GLP-1 prescribing in women is most clinically complex are precisely the populations for which Noom has published no outcomes.

LegitScript certification status. LegitScript is an independent verification body that certifies online pharmacies and telehealth prescribing platforms for compliance with pharmacy laws and prescribing standards. As of July 2025, Noom Med does not appear in LegitScript's directory of certified telehealth providers. This does not mean it is operating illegally, but it does mean it has not sought or obtained that independent credential.

Practical Steps If You Are Considering Noom Med

Before you enroll, ask these questions in writing and save the answers:

1. Is my medication compounded or brand-name, and from which facility?
2. Will my prescribing visit be synchronous (live video) or asynchronous (form review)?
3. What is the cancellation process, and how do I stop auto-renewal?
4. Does the platform have a protocol for women who become pregnant during treatment?
5. Who is my named prescribing clinician, and what is their state license number?

If you have PCOS, are perimenopausal, or are postmenopausal, ask specifically whether the coaching curriculum addresses your hormonal context. If the answer is no, that is information you need for your decision.

A woman with PCOS who wants GLP-1 therapy is better served by a platform or clinician that coordinates prescribing with gynecologic and reproductive care. A postmenopausal woman is better served by a provider who also addresses bone density, hormone therapy, and cardiovascular risk, all of which shift significantly in the GLP-1 context.

If you proceed with Noom Med, screenshot every billing confirmation, save every prescribing communication, and document your starting weight and any side effects from day one.